Kidneys and liver: tests for weight control

The liver and kidneys are two key "filters" of the body. The liver processes nutrients, synthesizes proteins, participates in fat and carbohydrate metabolism, and removes toxins. The kidneys filter the blood, maintain fluid and electrolyte balance, regulate blood pressure, and remove waste products. Excess weight places additional strain on these organs, and many medications for weight loss and associated metabolic diseases also pass through the liver and kidneys. [1]

Obesity is closely associated with the development of metabolically associated liver steatosis (the modern term MASLD, formerly non-alcoholic fatty liver disease) and steatohepatitis, which can lead to fibrosis and cirrhosis. Even a moderate weight loss of 5-10% can improve biochemical parameters and histological features of the liver. [2]

Excess weight increases the risk of chronic kidney disease, both directly and through type 2 diabetes, hypertension, and other factors. People with a body mass index (BMI) above 30 kg/m² are more likely to have a reduced estimated glomerular filtration rate (EGFR) and albuminuria. Early diagnosis can slow the decline in kidney function and help identify safer weight loss strategies. [3]

Modern reviews emphasize that structured weight loss with liver and kidney function monitoring improves not only appearance but also the course of MASLD, diabetes, and hypertension, and reduces the risk of cardiovascular and renal complications. It's not just the kilograms lost that are important, but also the quality of diet, physical activity, medication selection, and frequency of follow-up. [4]

The purpose of this article is to explain which tests help assess the condition of the liver and kidneys before starting a weight loss program, how to interpret them with your doctor, and how to manage weight loss in a way that protects rather than harms these organs. This is especially relevant for people with long-term obesity, diabetes, hypertension, or taking medications that affect the liver or kidneys. [5]

Table 1. Why you should check your liver and kidneys before losing weight

Cause	What does the check provide?
Frequent MASLD in obesity	Early detection of fatty liver disease
Risk of chronic kidney disease	Assessment of reserve function and early signs of damage
Choosing a weight loss strategy	Understanding whether medications can be used and which ones
Security control	Monitoring side effects of diets and medications
Health prognosis	Assessment of the risks of complications and potential reversibility of disorders

How does excess weight affect the liver and kidneys?

With excess adipose tissue, free fatty acids and inflammatory mediators accumulate in the liver, forming steatosis. Some patients remain in a relatively "harmless" stage of fatty liver, but a significant proportion develop inflammatory changes, steatohepatitis, fibrosis, and eventually cirrhosis. Clinical guidelines emphasize that MASLD is now considered a manifestation of a systemic metabolic disorder rather than a localized liver problem. [6]

Even moderate obesity increases liver enzyme activity in some patients, and severe obesity significantly increases the risk of severe steatosis and fibrosis. However, normal enzymes do not rule out MASLD, and the extent of damage is best assessed using a combination of biochemistry, noninvasive indices, elastography, and, if necessary, biopsy. Furthermore, it has been shown that a 7-10% weight loss can improve inflammation and fibrosis. [7]

Obesity affects the kidneys in several ways. First, it increases the filtration load, leading to hyperfiltration and glomerular hypertension. Second, obesity contributes to the development of diabetes and hypertension, which themselves damage the glomeruli and blood vessels. Third, visceral fat and inflammation lead to fat accumulation in renal tissue and impaired local regulation. [8]

Large meta-analyses show that obese individuals are more likely to have a glomerular filtration rate (GFR) below 60 ml/min and albuminuria compared to non-obese individuals. Furthermore, the duration and early onset of excess weight increase the risk, while weight loss can improve kidney function, particularly in patients with type 2 diabetes. [9]

It's important to understand that the liver and kidneys suffer not only from fat itself, but also from associated factors: sedentary lifestyle, poor diet, alcohol abuse, and the use of nephrotoxic and hepatotoxic medications. Therefore, a weight loss plan is considered part of an overall organ protection strategy, not a cosmetic measure. [10]

Table 2. The main consequences of obesity for the liver and kidneys

Organ	Possible consequences of obesity
Liver	MASLD, steatohepatitis, fibrosis, cirrhosis, enzyme elevations
Kidneys	Hyperfiltration, albuminuria, decreased filtration rate
Vessels	Atherosclerosis, high blood pressure, deterioration of renal blood flow
Metabolism	Type 2 diabetes, dyslipidemia, insulin resistance
General risk	Increased risk of chronic liver and kidney disease

Liver function tests to evaluate before weight loss

A basic liver evaluation typically includes a biochemical profile: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase, total bilirubin and its fractions, and albumin. Elevated ALT and AST in obesity often indicate MASLD, but these enzymes are nonspecific and may be altered in other liver diseases and extrahepatic conditions. [11]

Body mass index, waist circumference, triglyceride, cholesterol, glucose, and glycosylated hemoglobin levels help assess overall metabolic status and the likelihood of MASLD. Several noninvasive indices (e.g., FIB 4, NAFLD fibrosis score) are calculated taking into account age, enzymes, platelets, and albumin, allowing one to estimate the likelihood of significant fibrosis and decide whether more in-depth imaging is needed. [12]

Liver ultrasound is widely used for the initial detection of steatosis. It is accessible, safe, and relatively inexpensive, but its sensitivity decreases in mild steatosis and in individuals with severe obesity. Elastography and magnetic resonance imaging (MRI) are considered more informative, helping to assess tissue stiffness (an indirect indicator of fibrosis) and quantify the proportion of fat. [13]

Before initiating significant weight loss, and especially before prescribing medications to combat obesity, it is important to rule out other causes of liver damage, including viral hepatitis, alcohol-induced liver damage, autoimmune diseases, and genetic disorders. This may require specific markers, serological tests, and sometimes a biopsy. This approach allows for the accurate attribution of enzyme changes specifically to MASLD, rather than missing other pathologies. [14]

Clinical guidelines for MASLD emphasize that in cases of excess weight, regular monitoring of liver enzymes and fibrosis indices is necessary not only for diagnosis but also to assess the effect of weight loss. Improvements in ALT, AST, and GGT, reduction in steatosis on imaging, and stabilization of fibrosis indices during weight loss are considered significant positive outcomes of therapy. [15]

Table 3. Basic tests and methods for assessing liver function in overweight patients

Method or indicator	What does it show?	When it is especially important
ALT, AST	Liver cellular damage	Suspected MASLD, therapy monitoring
GGT, alkaline phosphatase	Cholestasis, damage to the bile ducts	When combined with elevated bilirubin
Bilirubin, albumin	Synthetic function of the liver	If advanced fibrosis is suspected
Ultrasound of the liver	Presence and degree of steatosis	Initial screening for obesity
Elastography	Tissue stiffness, indirect fibrosis	At increased risk of progression
Non-invasive fibrosis indices	Probability of significant fibrosis	Decision on further examination

Tests to assess kidney function before weight loss

A basic assessment of kidney function includes serum creatinine and estimated glomerular filtration rate using standard formulas. This is used to determine the stage of chronic kidney disease. However, in obesity, adjustment for body surface area may underestimate actual filtration, so interpretation requires caution, especially in individuals with a very high body mass index. [16]

Additionally, albuminuria or total protein in the urine is assessed, most often as the albumin-to-creatinine ratio in a single urine sample. Increased albuminuria is considered an early sign of glomerular damage in diabetes and obesity, even when the filtration rate is still within the normal range. The combination of a moderate decrease in filtration and albuminuria increases the risk of adverse outcomes. [17]

A general urine analysis provides information on the density, presence of red blood cells, white blood cells, and casts, which helps identify concomitant infections, inflammatory processes, or other injuries. When planning weight loss and adjusting therapy, this data is important for choosing a safe physical activity regimen and medications, especially diuretics, antihypertensive agents, and drugs that affect the renin-angiotensin-aldosterone system. [18]

For people with a combination of obesity, diabetes, and hypertension, more frequent kidney function testing is recommended, as weight loss and dietary changes can impact blood pressure, glucose levels, and medication needs. Recent reviews have shown that structured weight loss in diabetes improves filtration rates and albuminuria, but requires careful monitoring to prevent sharp fluctuations in blood pressure and dehydration. [19]

For patients already diagnosed with chronic kidney disease, a weight loss plan should be chosen with particular caution. Protein restriction should not be excessive, so as not to exacerbate muscle loss, and dehydration due to intensive diets or excessive diuretic load can accelerate the decline in filtration. Consensus documents emphasize the need for individualized protein and calorie intake based on the stage of kidney disease. [20]

Table 4. Tests for assessing kidney function in overweight people

Analysis or method	What does it evaluate?	Comments
Creatinine and estimated filtration	General function of the glomeruli	Possible underestimation in people with severe obesity
Albumin creatinine in urine	Early glomerular failure	Important for diabetes and hypertension
General urine analysis	Infections, inflammation, bleeding	Completes the picture in case of deviations
Electrolytes, urea	Water-electrolyte balance, nitrogen metabolism	Important for intensive diets and diuretic use
Repeated measurements	Dynamics of the function	Helps distinguish temporary fluctuations from a trend

How to safely lose weight while taking into account your liver and kidney health

For most overweight people with moderate liver and kidney function abnormalities, lifestyle modification remains the cornerstone of treatment: moderate calorie reduction, increased physical activity, and improved nutrition. Guidelines for MASLD and obesity recommend aiming for a 7-10% body weight loss over 6-12 months, which is usually sufficient for clinically significant improvement in liver function tests. [21]

A moderately low-calorie Mediterranean diet is considered preferable: plenty of vegetables, fruits, whole grains, legumes, fish, healthy fats, and a minimum of ultra-processed foods, sugar, and saturated fats. This approach improves not only weight and liver enzymes, but also lipid profiles, insulin sensitivity, and inflammatory markers, and in patients with MASLD, it is associated with reduced steatosis and fibrosis. [22]

In the presence of chronic kidney disease, dietary adaptation is required: monitoring total protein intake, sodium, and, in advanced stages, potassium and phosphorus. Consensus documents on obesity and kidney disease emphasize the need to carefully balance calorie reduction with preventing muscle loss and excessive protein restriction. A nephrologist and clinical nutritionist are often consulted for this purpose. [23]

Physical activity should be selected based on overall health, joint health, cardiovascular risk, and kidney function. Moderate aerobic exercise and strength training help reduce visceral fat, improve insulin sensitivity and liver health, and protect muscle mass while reducing calories. In patients with advanced kidney disease and severe heart disease, the intensity and volume of exercise should be discussed with a doctor. [24]

It is important to avoid extreme diets, severe dehydration, and unproven supplements for liver "cleansing" or "diuretic" effects. Such practices can dramatically impair kidney function, worsen electrolyte imbalances, and trigger a worsening of liver disease. A sustainable calorie deficit, a reasonable fluid intake based on kidney disease recommendations, and a gradual increase in activity are considered safer. [25]

Table 5. Approximate approach to weight loss with mild laboratory abnormalities

Situation	Recommended steps
Moderately elevated liver enzymes, no fibrosis	Mediterranean low-calorie diet, plus activity
Mild decrease in filtration without albuminuria	Careful calorie deficit, blood pressure and sugar control
Albuminuria with normal filtration	Focus on diabetes and hypertension control, gradual weight loss
Obesity with MASLD without severe fibrosis	Goal: minus 7-10% of mass, enzyme and elastography monitoring
Obesity with early chronic kidney disease	Joint plan of a nephrologist and nutritionist, individual restrictions

Weight Loss Medications and Surgeries: Specific Considerations for Liver and Kidney Disease

When lifestyle changes are insufficient, anti-obesity medications and, in severe cases, bariatric surgery are considered. Current guidelines and research show that glucagon-like peptide type 1 receptor agonists and similar drugs provide significant weight loss and have a beneficial effect on the liver, reducing steatosis and inflammation, and also demonstrate cardiovascular and renal benefits. [26]

For each class of medication, limitations on liver and kidney function are important. Reviews and national guidelines indicate that some combination medications (e.g., naltrexone plus bupropion, phentermine plus topiramate) require caution in moderate renal impairment and are contraindicated in end-stage renal disease. They may also cause hepatotoxicity in vulnerable patients. Regular monitoring of enzymes and filtration is essential. [27]

Orlistat, which acts in the intestinal lumen, is virtually not absorbed and has traditionally been considered relatively safe in patients with moderate liver and kidney impairment. However, cases of kidney stones and rare severe liver damage have been reported, and caution is required in patients with chronic kidney disease due to potential changes in absorption and interactions with other medications. [28]

GLP-1 agonists and related drugs are considered the preferred pharmacotherapy for obesity in patients with MASLD and increased cardiorenal risk, as they simultaneously reduce body weight, improve glycemia, and reduce the risk of cardiovascular and renal events. However, in advanced liver and renal failure, the regimen and dosage are selected individually, taking into account the package insert and clinical guidelines. [29]

Bariatric surgery provides the greatest and most sustainable weight loss and has been shown to improve the course of MASLD and reduce the risk of chronic kidney disease progression. However, this intervention requires careful preoperative evaluation of the liver and kidneys, assessment of the stage of fibrosis and associated risks, and lifelong monitoring of nutritional status and organ function. [30]

Table 6. Examples of anti-obesity methods and features in case of organ dysfunction

Method or drug	Liver	Kidneys
GLP 1 agonists	Improve MASLD, require monitoring	May benefit kidneys, dosage according to guidelines
Orlistat	Rare hepatotoxicity	Caution in chronic kidney disease
Naltrexone plus bupropion	Risk of hepatotoxicity	Restrictions for moderate and severe deficiency
Phentermine plus topiramate	Possible stress on the liver	Risk of reduced filtration
Bariatric surgery	Improves MASLD	Improves prognosis, requires preoperative assessment

A practical guide: when to see a doctor, how often to get tested, and what to ask

The first step before starting a weight loss program is a visit to a general practitioner or a physician who manages the patient's diabetes, hypertension, or other chronic conditions. At this stage, weight loss goals are discussed, a liver and kidney history is collected, current medications and risk factors are assessed, and initial tests are ordered. [31]

If initial tests reveal significant abnormalities (significantly elevated liver enzymes, decreased filtration, severe albuminuria), the doctor may refer the patient to a gastroenterologist, hepatologist, or nephrologist. These specialists help refine the diagnosis, stage the disease, determine whether lifestyle modifications are sufficient or medications are needed, and determine the frequency of monitoring. [32]

During weight loss, liver and kidney function tests are typically repeated every 3-6 months, and more frequently when using medications, according to the drug's instructions and recommendations. For patients with MASLD and chronic kidney disease, more intensive monitoring schedules may be required, especially during the first months of diet and activity changes, when there is a risk of dehydration, hypotension, or deterioration in these parameters. [33]

During your appointment, it's important to discuss not only test results but also symptoms: weakness, swelling, shortness of breath, pain in the right upper quadrant, changes in urine color, and decreased urine output. Sudden changes in well-being during dieting, active weight loss, or medication initiation are a reason for an unscheduled liver and kidney evaluation and possible treatment adjustments. [34]

It's helpful to prepare a list of questions in advance: how safe are the chosen weight loss methods for the liver and kidneys, what specific indicators will be monitored, what signs require immediate attention, and when is the next follow-up appointment. A clear monitoring plan helps reduce anxiety and improve adherence to long-term obesity treatment. [35]

Table 7. Approximate frequency of blood tests during weight loss

Situation	Recommended inspection frequency (approximate)
No chronic diseases, moderate obesity	Start, then every 6-12 months
MASLD without significant fibrosis	Start, then every 6 months
Early chronic kidney disease	Start, then every 3-6 months
Taking medications for weight loss	Start, then according to the drug regimen, often once every 3 months
Severe deviations or rapid weight loss	Individually, sometimes monthly at the beginning of therapy

Brief FAQ

1. Is it possible to start a strict diet without tests if you feel well?
This is risky. Some people with MASLD and early chronic kidney disease are asymptomatic. Severe calorie restrictions, dehydration, and untested supplements can worsen underlying conditions. A minimal set of liver and kidney tests before making major lifestyle changes is significantly safer than relying solely on how you feel. [36]

2. Will liver and kidney function tests improve if I simply lose weight without medication?
Yes, in many cases, moderate weight loss already improves these parameters. For the liver, losing 5-10% of body weight has been shown to reduce steatosis, inflammation, and fibrosis. For the kidneys, weight loss has been shown to reduce albuminuria and stabilize filtration, especially in diabetes and hypertension. However, this does not eliminate the need to monitor and treat concomitant diseases. [37]

3. Are modern "weight loss injections" safe for people with liver and kidney problems?
GLP-1 receptor agonists and related drugs generally show a favorable profile for the liver and kidneys, but in severe organ failure, they require individual selection and monitoring. The decision should be made only with a doctor, taking into account the stage of MASLD and chronic kidney disease, concomitant medications, and the risk of side effects. [38]

4. Can liver ultrasound alone be used as a guide without further testing?
No. Ultrasound is a good indicator of steatosis, but it doesn't reflect the liver's synthetic function, doesn't provide a complete picture of inflammation, and isn't a substitute for fibrosis assessment. Biochemical parameters, fibrosis indices, and, if necessary, elastography complement each other. The same applies to the kidneys: visualization alone, without laboratory data, doesn't allow for an assessment of filtration. [39]